Table 1.
Current Therapeutic Options for Clear Cell RCC Therapy
| Setting | Phase III Trials | Alternatives |
|---|---|---|
| First-line therapy | ||
| Good or intermediate riskb | Sunitinib or Bevacizumab plus IFN or pazopanib | High-dose IL-2, IFN |
| Poor riskb | Temsirolimus | Sunitinib |
| Second-line therapy | ||
| Prior cytokine | Sorafenib | Sunitinib or bevacizumab |
| Prior VEGFR inhibitor | Everolimus | Other VEGF targeted therapy |
| Prior mTOR inhibitor | Clinical trials | Clinical trials |
a
Abbreviations: IL-2, interleukin 2; IFN, IFN alpha; VEGF, vascular endothelial growth factor
b
Memorial Sloan-Kettering Cancer Center risk status.